Clinical Trial Update: to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating HLX10 with chemotherapy as neoadjuvant therapy and HLX10 with placebo as adjuvant therapy versus control in triple negative br…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• HLX10

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Triple Negative Breast Cancer | Phase 3 | Status: NOT_YET_RECRUITING